Daniel J George1, William G Kaelin. Show Affiliations » 1. Dana-Farber Cancer Institute, Boston, USA.
Abstract
Entities: Disease Gene
Mesh： See more » Adenocarcinoma, Clear Cell/drug therapyAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedBevacizumabCarcinoma, Renal Cell/drug therapyDisease-Free SurvivalEndothelial Growth Factors/antagonists & inhibitorsGene SilencingGenes, Tumor SuppressorHumansIntercellular Signaling Peptides and ProteinsKidney Neoplasms/drug therapyLigases/geneticsLymphokines/antagonists & inhibitorsNeovascularization, Pathologic/drug therapyTumor Suppressor ProteinsUbiquitin-Protein LigasesVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsVon Hippel-Lindau Tumor Suppressor Protein
Substances： See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedEndothelial Growth FactorsIntercellular Signaling Peptides and ProteinsLymphokinesTumor Suppressor ProteinsVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsBevacizumabUbiquitin-Protein LigasesVon Hippel-Lindau Tumor Suppressor ProteinLigasesVHL protein, human
Year: 2003 PMID： 12890838 DOI： 10.1056/NEJMp030061
Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245